MedTrace Logo

Staphylococcal Acute Post-Operative PJI Treated With 'DAIR' And Impact Of Rifampin

NCT03750721 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 79

Last updated 2018-11-23

No results posted yet for this study

Summary

S. aureus and coagulase-negative staphylococci are the most frequent bacteria responsible for PJI (prosthetic joint infection). The aim of this study is to describe the use of rifampicin.

Conditions

  • Bone and Joint Infection
  • Antibiotic Resistant Staphylococcus Aureus Infection

Interventions

OTHER

Role of rifampin in staphylococcal PJI

the aim is to determine if the dose and the duration of rifampin influenced the prognosis

Sponsors & Collaborators

  • Hospices Civils de Lyon

    lead OTHER

Principal Investigators

  • Tristan FERRY, Md,PhD · Hospices Civils de Lyon Hôpital de la Croix-Rousse

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-04-01
Primary Completion
2018-05-01
Completion
2018-05-01

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03750721 on ClinicalTrials.gov